-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
CanaQuest Achieves Statistically Significant Reduction of Seizures for Epilepsy Compared to Standard CBD
CanaQuest Achieves Statistically Significant Reduction of Seizures for Epilepsy Compared to Standard CBD
Drug Candidate, CQ-001 (cannabidiol "CBD" + IP formula), also demonstrated substantially reduced seizures at higher doses, with less CBD, compared to standard CBD.
TORONTO, ON / ACCESSWIRE / December 8, 2022 / CANAQUEST MEDICAL CORP (OTC PINK:CANQF) (the "Company" or "CanaQuest"), a clinical-stage life sciences company focused on drug discovery and development of next-generation targeted cannabinoid therapeutics for the central nervous system (CNS), today announced Statistically Significant efficacy results from the Clinical Dose & Efficacy Study ("Study") conducted by Dr. W McIntyre Burnham, emeritus professor of the University of Toronto's Temerty Faculty of Medicine. In comparison to standard CBD, CQ-001 (cannabidiol "CBD" + IP formula - essential fatty acids) demonstrated 40% more seizure reduction at a medium dose in the maximal electroshock seizure (MES) model. This result indicates that CQ-001 is stronger than standard CBD, and could be used a lower dose to achieve seizure control.
Highlights derived from the Study are as follows:
- The enhanced efficacy from these clinical studies further validates the pre-clinical trial results obtained by Dr. Steven Laviolette, a professor and neuroscientist, at Western University.
- These results set the stage for substantially smaller dosages of CBD generating the desired results without the negative side effects and will define a dosage of CQ-001 for a clinical trial (Phase II/III, double-blind trial, 60 patients).
- CanaQuest has identified the regulatory pathways to obtain Rx Drug Identification Numbers (DINs) in Canada and the USA for Epilepsy rare neurological conditions. CQ-001, in combination with its proprietary processing and delivery method, is estimated to be approved in about 3 years.
"Further testing will be necessary, however preliminary tests suggest that CQ-001 is stronger than regular CBD," said Burnham, pharmacologist and co-director of EpLink.
Paul Ramsay, President, stated, "The Clinical Study results reconfirm the pre-clinical trial results conducted at Western University, and further substantiate the magnitude of this life-changing discovery."
Physicians, psychiatrists, pharmacists, and healthcare practitioners interested in joining our growing network can contact paul@canaquest.com.
About: The Ontario Brain Institute - EpLink
The Ontario Brain Institute is a provincially funded, not-for-profit organization that accelerates discovery and innovation, benefiting both patients and the economy.
EpLink is the Epilepsy Research Program of the Ontario Brain Institute and is focused on finding new ways to diagnose, treat and improve the lives of people living with drug-resistant epilepsy. The program is funded by the Ontario Brain Institute and aims to bring health innovations directly to the epilepsy community.
About: CanaQuest Medical Corp
CanaQuest Medical, a clinical-stage, life sciences company, is focused on the drug discovery and development of next-generation targeted therapeutics within the endocannabinoid system and specific brain receptors. The Company is focused on treating neurological conditions, such as epilepsy, anxiety, depression, and Post Traumatic Stress Disorder "PTSD", including addiction.The Company is the industry partner for research and product development with Dr. Steven Laviolette, a professor, and neuroscientist, with decades of experience in the field of mental health and cannabinoids, at Western University. Dr. Laviolette and his team of 13 scientists made two amazing discoveries that are drug candidates targeting neurological conditions: Drug candidate,CQ-001, supported by (cannabidiol "CBD" + IP formula) - molecules bond and synergistically attach to PPAR receptors allowing CQ-001 to cross the blood-brain barrier (BBB) to target the central nervous system (the brain) with amplified effects and efficacy. CBD by itself did not do this in the pre-clinical trial research. The second Drug candidate, CQ-002, supported by (cannabinoid "THC" + IP formula), is a safer alternative to all other THC products based on pre-clinical trial results. An OTC (less potent version) of CQ-001, branded as Mentanine®, targeting anxiety, depression, and PTSD (without claims), is available for sale via in the US.
Acknowledgement:
CanaQuest has been named: 2022 Global Excellence Awards
Best Medical Cannabis and Botanical Oils Product Development Company, 2022 North America
- awarded by Global Health & Pharma, UK.
CANAQUEST CONTACT:
Paul Ramsay, President
CanaQuest Medical Corp
paul@canaquest.com
Tel: 416.704.3040
SOURCE: CanaQuest Medical Corp.
View source version on accesswire.com:
Drug Candidate, CQ-001 (cannabidiol "CBD" + IP formula), also demonstrated substantially reduced seizures at higher doses, with less CBD, compared to standard CBD.
候选药物CQ-001(大麻二醇“CBD”+ip公式)与标准CBD相比,在较高剂量时也显示出显著减少癫痫发作的作用,CBD较少。
TORONTO, ON / ACCESSWIRE / December 8, 2022 / CANAQUEST MEDICAL CORP (OTC PINK:CANQF) (the "Company" or "CanaQuest"), a clinical-stage life sciences company focused on drug discovery and development of next-generation targeted cannabinoid therapeutics for the central nervous system (CNS), today announced Statistically Significant efficacy results from the Clinical Dose & Efficacy Study ("Study") conducted by Dr. W McIntyre Burnham, emeritus professor of the University of Toronto's Temerty Faculty of Medicine. In comparison to standard CBD, CQ-001 (cannabidiol "CBD" + IP formula - essential fatty acids) demonstrated 40% more seizure reduction at a medium dose in the maximal electroshock seizure (MES) model. This result indicates that CQ-001 is stronger than standard CBD, and could be used a lower dose to achieve seizure control.
多伦多,on/ACCESSWIRE/2022年12月8日/CANAQUEST医疗公司(场外粉色:CANQF)(“公司”或“CanaQuest”"), 一家临床阶段的生命科学公司今天宣布,该公司专注于中枢神经系统(CNS)下一代靶向大麻类药物的药物发现和开发具有统计意义疗效由多伦多大学特梅蒂医学院名誉教授W·麦金太尔·伯纳姆博士进行的临床剂量和疗效研究(“研究”)得出。与标准CBD相比,CQ-001(大麻二酚“CBD”+IP配方-必需脂肪酸)在最大电休克发作(MES)模型中,中等剂量的癫痫发作减少40%。这一结果表明,CQ-001比标准CBD更强,可以使用较低的剂量来实现癫痫控制。
Highlights derived from the Study are as follows:
这项研究的要点如下:
- The enhanced efficacy from these clinical studies further validates the pre-clinical trial results obtained by Dr. Steven Laviolette, a professor and neuroscientist, at Western University.
- These results set the stage for substantially smaller dosages of CBD generating the desired results without the negative side effects and will define a dosage of CQ-001 for a clinical trial (Phase II/III, double-blind trial, 60 patients).
- CanaQuest has identified the regulatory pathways to obtain Rx Drug Identification Numbers (DINs) in Canada and the USA for Epilepsy rare neurological conditions. CQ-001, in combination with its proprietary processing and delivery method, is estimated to be approved in about 3 years.
- 这些临床研究的增强疗效进一步证实了西方大学教授兼神经学家史蒂文·拉维奥莱特博士获得的临床前试验结果。
- 这些结果为更小剂量的CBD产生预期结果奠定了基础没有负面的副作用并将确定临床试验(II/III期,双盲试验,60名患者)的CQ-001剂量。
- CanaQuest已经确定了在加拿大和美国获得Rx药物识别号(DINS)的监管途径,用于治疗罕见的神经系统癫痫。CQ-001,结合其专有的加工和交付方法,估计为在大约3年内获得批准.
"Further testing will be necessary, however preliminary tests suggest that CQ-001 is stronger than regular CBD," said Burnham, pharmacologist and co-director of EpLink.
EPLink的药理学家兼董事联合创始人伯纳姆说:“尽管初步测试表明CQ-001比普通的CBD更强,但仍有必要进行进一步的测试。”
Paul Ramsay, President, stated, "The Clinical Study results reconfirm the pre-clinical trial results conducted at Western University, and further substantiate the magnitude of this life-changing discovery."
总裁保罗·拉姆齐说:“临床研究结果再次证实了在西方大学进行的临床前试验结果,并进一步证实了这一改变人生的发现的重大意义。”
Physicians, psychiatrists, pharmacists, and healthcare practitioners interested in joining our growing network can contact paul@canaquest.com.
有兴趣加入我们不断扩大的网络的医生、精神病学家、药剂师和保健从业者可以联系Paul@canaquest.com。
About: The Ontario Brain Institute - EpLink
关于:安大略省脑研究所-EpLink
The Ontario Brain Institute is a provincially funded, not-for-profit organization that accelerates discovery and innovation, benefiting both patients and the economy.
安大略省脑研究所是一个由省政府资助的非营利性组织,旨在加速发现和创新,使患者和经济都受益。
EpLink is the Epilepsy Research Program of the Ontario Brain Institute and is focused on finding new ways to diagnose, treat and improve the lives of people living with drug-resistant epilepsy. The program is funded by the Ontario Brain Institute and aims to bring health innovations directly to the epilepsy community.
EpLink是安大略省脑研究所的癫痫研究计划,专注于寻找新的方法来诊断、治疗和改善耐药癫痫患者的生活。该项目由安大略省脑研究所资助,旨在将健康创新直接带给癫痫社区。
About: CanaQuest Medical Corp
关于:CanaQuest医疗公司
CanaQuest Medical, a clinical-stage, life sciences company, is focused on the drug discovery and development of next-generation targeted therapeutics within the endocannabinoid system and specific brain receptors. The Company is focused on treating neurological conditions, such as epilepsy, anxiety, depression, and Post Traumatic Stress Disorder "PTSD", including addiction.The Company is the industry partner for research and product development with Dr. Steven Laviolette, a professor, and neuroscientist, with decades of experience in the field of mental health and cannabinoids, at Western University. Dr. Laviolette and his team of 13 scientists made two amazing discoveries that are drug candidates targeting neurological conditions: Drug candidate,CQ-001, supported by (cannabidiol "CBD" + IP formula) - molecules bond and synergistically attach to PPAR receptors allowing CQ-001 to cross the blood-brain barrier (BBB) to target the central nervous system (the brain) with amplified effects and efficacy. CBD by itself did not do this in the pre-clinical trial research. The second Drug candidate, CQ-002, supported by (cannabinoid "THC" + IP formula), is a safer alternative to all other THC products based on pre-clinical trial results. An OTC (less potent version) of CQ-001, branded as Mentanine®, targeting anxiety, depression, and PTSD (without claims), is available for sale via in the US.
CanaQuest Medical是一家临床阶段的生命科学公司,专注于内源性大麻素系统和特定大脑受体内下一代靶向疗法的药物发现和开发。该公司专注于治疗神经疾病,如癫痫、焦虑、抑郁和包括成瘾在内的创伤后应激障碍“PTSD”。该公司是西部大学教授和神经学家史蒂文·拉维奥莱特博士的研究和产品开发的行业合作伙伴,他在精神健康和大麻类药物领域拥有数十年的经验。LaViette博士和他的13名科学家团队做出了两项令人惊叹的发现,这两项发现是针对神经疾病的候选药物:候选药物CQ-001,由(大麻二酚“CBD”+IP公式)支持--分子结合并协同结合到PPAR受体上,使CQ-001能够跨越血脑屏障(BBB),以放大的效果和效率靶向中枢神经系统(大脑)。CBD本身并没有在临床前试验研究。第二个候选药物CQ-002,由(大麻素“THC”+IP)支持公式),是一种更安全的替代方案基于临床前试验结果的所有其他THC产品。CQ-001的非处方药(效力较低的版本), 品牌为Mentanine®,针对焦虑、抑郁和创伤后应激障碍(无索赔),在美国可通过VIA销售。
Acknowledgement:
致谢:
CanaQuest has been named: 2022 Global Excellence Awards
CanaQuest已命名为:2022年全球卓越奖
Best Medical Cannabis and Botanical Oils Product Development Company, 2022 North America
2022年北美最佳医用大麻和植物油产品开发公司
- awarded by Global Health & Pharma, UK.
-由英国Global Health&Pharma颁发。
CANAQUEST CONTACT:
CANAQUEST联系方式:
Paul Ramsay, President
CanaQuest Medical Corp
paul@canaquest.com
Tel: 416.704.3040
保罗·拉姆齐,总裁
CanaQuest医疗公司
邮箱:Paul@canaquest.com
电话:416.704.3040
SOURCE: CanaQuest Medical Corp.
资料来源:CanaQuest医疗公司
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧